Everything tagged "ipo" across the TickerSpark archives.
Advasa Holdings, Inc. (NASDAQ: ADBT) is expected to list on 2026-08-17, but the company has not disclosed a price range yet. It is offering 94,046,357 shares. The setup looks like a fast-growing EWA software story with real revenue momentum, but investors should watch the concentrated ownership, regulatory exposure, and how much of the float actually comes to market.
Thunder Bridge Capital Partners V L is expected to list on NASDAQ on 2026-08-13, with the price range not yet disclosed. The SPAC is offering 26,100,000 shares and is targeting a $261,000,000 market cap. Watch whether the sponsor’s fintech angle and prior Thunder Bridge track record can support demand before pricing.
Northern Lights Fund Trust III is expected to list on the NYSE on 2026-08-14, but the price range has not been disclosed. The filing set does not show a traditional operating-company IPO; it points to an existing Delaware statutory trust used to launch and administer funds. Watch whether investors treat this as a fund-platform story or pass until there is clearer pricing and a specific series-level catalyst.
Gores Holdings XI, Inc. Class A Ordinary Shares (NASDAQ: GHXI) is expected to list on 2026-08-13, but the price range has not been disclosed. This is a SPAC, so the real question is not near-term revenue — it is whether the Gores team can source a strong deal before dilution and redemption risk bite.
Vogenx Inc Common Stock is expected to list on NASDAQ on 2026-08-12, but the price range has not been disclosed. The company is a clinical-stage biopharma name focused on metabolic disorders, including post-bariatric hypoglycemia and gastroparesis. The setup favors investors who want an early-stage catalyst story, but shareholders should watch the capital needs and clinical risk closely.
Pelican Acquisition II Corporation Right (NASDAQ: PLCIR) is expected to list on 2026-08-12, but the price range has not been disclosed yet. This is a SPAC/right offering, not an operating company IPO, so the key question is whether the sponsor can source a credible technology deal. Watch the trust structure and dilution; the setup favors investors who are comfortable underwriting a blank-check search process.
Braveheart Bio has a credible bull case as insider-aligned capital backs a lead program with positive Phase 2 data and a late-stage path. The single-asset risk is real, but the size of recent buying makes today’s IPO pullback look more like volatility than a thesis break.
Lyntris Inc. (NYSE: LYNX) is expected to list on 2026-08-19 at a price range of $19.00 to $22.00 per share. The company is offering 24,000,000 shares, with a disclosed market cap of $607,200,000 if priced at the top of the range. The bull case is a defense-tech platform built around sensing, AI-driven data fusion, and mission systems; the bear case is that key IPO financials and filing details have not been publicly disclosed in the sources found.
CSRA Inc. is listed as expected to debut on the NYSE on 2026-08-12, but the price range has not been disclosed. The key issue is that the company’s SEC filings show CSRA already filed an S-1 in 2015 and was later acquired in 2018, so investors should watch this calendar entry closely for accuracy before treating it like a fresh IPO.
DPC is posting strong revenue and EBITDA growth, but its heavy debt load and negative book value keep the stock in Hold territory. The growth story is supported by aerospace and industrial gas turbine demand, yet the balance sheet leaves little room for error.
Guinness Atkinson Funds is expected to list on the NYSE on 2026-08-12, but the price range has not been disclosed. The bigger question is whether this is really an IPO at all, or a routine SEC fund filing for an existing investment company. Bull case: ETF-class expansion in a regulated fund family. Bear case: no IPO economics, no pricing, and no operating-company growth story.
Valued Advisers Trust is expected to list on 2026-08-12 on the NYSE, but the price range has not been disclosed. The key issue is that the SEC materials reviewed do not show a traditional operating-company IPO; they describe a long-running registered investment company platform instead. That makes this a watch-the-structure story more than a standard growth IPO.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime